Immune system and alcoholic liver disease;Sistema inmune y enfermedad hepática por alcohol

Medicina Clinica

Volumn 125, Issue 7, 2005, Pages 263-269

  Laso, Francisco Javier ^a   Pastor, Isabel ^a,b   Orfao, Alberto ^c  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Alcohol; Alcohol liver disease; Alcoholism; Cytokines

Indexed keywords

ADIPONECTIN; ALCOHOL; ANTIOXIDANT; CHEMOKINE; CYTOKINE; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; PENTOXIFYLLINE; PLATELET DERIVED GROWTH FACTOR; PREDNISONE; PROTEIN INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALCOHOL ABUSE; ALCOHOL LIVER DISEASE; APOPTOSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC LYMPHOCYTE; DISEASE SEVERITY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFECTION; INFLAMMATION; LIVER FIBROSIS; LIVER NECROSIS; LYMPHOCYTE ACTIVATION; PATHOGENESIS; REVIEW; RISK FACTOR; STELLATE CELL;

EID: 25144464441     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13078101     Document Type: Review

References (90)

1. McGregor RR. Alcohol and inmune defense. JAMA. 1986;256:1474-9.
2. Szabo G. Consequences of alcohol consumption on host defense. Alcohol Alcohol. 1999;34:830-41.
3. Nelson S, Kolls JK. Alcohol, host defense and society. Nat Rev Immunol. 2002;2:205-9.
4. Liu YK. Phagocytic capacity of RES in alcoholics. J Reticuloendothel Soc. 1979;25:605-13.
5. Laso FJ, Madruga JI, Girón JA, López A, Ciudad J, San Miguel JF, et al. Decreased natural killer cytotoxic activity in chronic alcoholism is associated with alcohol liver disease but not ethanol consumption. Hepatology. 1997;25:1096-100.
6. Song Z, Joshi-Barve S, Barve S, McClain CJ. Advances in alcoholic liver disease. Curr Gastroenterol Rep. 2004;6:71-6.
7. Lieber CS. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr Gastroenterol Rep. 2004;6:60-5.
8. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343:1467-76.
9. Hanck C, Manigold T, Böcker U, Kurimoto M, Kölbel CB, Singer MV, et al. Gene expression of interleukin 18 in unstimualted peripheral blood mononuclear cells of patients with alcoholic cirrhosis. Gut. 2001;49:106-11.
10. Cook RT, Garvey MJ, Booth BM, Goeken JA, Stewart B, Noel M. Activated CD-8 cells and HLA DR expression in alcoholic without overt liver disease. J Clin Immunol. 1991;11:246-53.
11. Kronfol Z, Nair M, Hill E, Kroll Ph, Brower K, Greden J. Immune function in alcoholism: a controlled study. Alcohol Clin Exp Res. 1993;17:279-83.
12. Laso FJ, Madruga JI, San Miguel JF, Ciudad J, López A, Álvarez-Mon M, et al. Long lasting immunological effects of ethanol after withdrawal. Cytometry. 1996;26:275-80.
13. Laso FJ, Madruga JI, López A, Ciudad J, Álvarez-Mon M, San Miguel JF, et al. Distribution of peripheral blood lymphoid subsets in alcoholic liver cirrhosis: Influence of ethanol intake. Alcohol Clin Exp Res. 1996;20:1564-8.
14. Laso FJ, Madruga JI, López A, Ciudad J, Álvarez-Mon M, San Miguel JF, et al. Abnormalities of peripheral blood T lymphocytes and natural killer cells in alcoholic hepatitis persist after a 3-month withdrawal period. Alcohol Clin Exp Res. 1997;21:672-6.
15. Santos JL, Díez A, Luna L, Soto JA, Wachter H, Fuchs D, et al. T-cell activation, expression of adhesion molecules and response to ethanol in alcoholic cirrhosis. Immunol Lett. 1996;50:179-83.
16. Song K, Coleman RA, Alber C, Ballas ZK, Waldschmidt TJ, Mortari F, et al. Th1 cytokine response of CD57+ T-cell susbsets in healthy controls and patients with alcoholic liver disease. Alcohol. 2001;24:155-67.
17. Jerrells TR. Role of actived CD8+ T cells in the initiation and continuation of hepatic damage. Alcohol. 2002;27:47-52.
18. Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patiens. Hepatology. 1991;13:267-76.
19. Hill DB, Marsano LS, McClain CJ. Increased plasma interleukin-6 activity in alcoholic hepatitis. J Lab Clin Med. 1992;119:547-52.
20. Hill DB, Marsano LS, McClain CJ. Increased plasma interleukin-8 concentrations in alcoholic hepatitis. Hepatology. 1993;18:576-80.
21. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology. 1989;9:349-51.
22. McClain CJ, Hill D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liver Dis. 1993;13:170-82.
23. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis. 1999;19:205-19.
24. Diehl AM. Cytokines and the molecular mechanisms of alcoholic liver disease. Alcohol Clin Exp Res. 1999;23:1419-24.
25. Neuman MG, Brenner DA, Rehermann B, Taieb J, Chollet-Martin S, Cohard M, et al. Mechanisms of alcoholic liver disease: cytokines. Alcohol Clin Exp Res. 2001;25:251S-3S.
26. Lieber CS. Alcohol liver injury: pathogenesis and therapy in 2001. Pathol Biol. 2001;49:738-52.
27. Sun AY, Ingelman-Sundberg M, Neve E, Matsumoto H, Nishitani Y, Minowa Y, et al. Ethanol and oxidative stress. Alcohol Clin Exp Res. 2001;25:237S-43S.
28. Hoek JB, Pastorino JG. Etanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol. 2002;27:63-8.
29. Neuman MG, Katz GG, Malkiewicz IM, Mathurin P, Tsukamoto H, Adachi M, et al. Alcohol liver injury and apoptosis. Alcohol Clin Exp Res. 2002;28:117-28.
30. McClain CJ, Barve S, Barve S, Deaciuc I, Hill DB. Tumor necrosis factor and alcoholic liver disease. Alcohol Clin Exp Res. 1998;22:248S-52S.
31. Hill DB. Increased monocyte nuclear factor-kappaB activation and tumor necrosis factor production in alcoholic hepatitis. J Lab Clin Med. 2000;135:387-95.
32. García Ruíz P, Canora J, Díez A, Fuchs D, Wachter H. Receptores solubles de la interleucina 2 y del factor de necrosis tumoral en la cirrosis hepática de diversas etiologías. Relación con el pronóstico y la gravedad clínica. Med Clín (Barc). 2004;122:441-3.
33. Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology. 1994;20:453-60.
34. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, et al. Essential role of tumor necrosis factor alpha in alcohol induced liver injury in mice. Gastroenterology. 1999;117:942-52.
35. Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG. Antibodies to tumor necrosis factor alfa atenuate hepatic necrosis and inflammation caused by chronic exposure to etanol in the rat. Hepatology. 1997;26:1530-7.
36. Szabo G, Mandrekar P, Newman L, Catalano D. Regulation of human monocyte functions by acute ethanol treatment: Decreased TNF alpha, IL-1 beta and elevated IL-10, and TGF beta production. Alcohol Clin Exp Res. 1996;20:900-7.
37. Batey R, Cao Q, Pang G, Russel A, Clancy R. Decreased tumor necrosis factor alpha and interleukin-1 production from intrahepatic mononuclear cells in chronic ethanol consumption and upregulation by endotoxin. Alcohol Clin Exp Res. 1998;22:150-6.
38. Presson J. Alcohol and the small intestine. Scand J Gastroenterol. 1991;26:3-15.
39. Parlesak, Schafer C, Schutz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol. 2000;32:742-7.
40. Hanck C, Rossol S, Bocker U, Tokus M, Singer MV. Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrosis. Alcohol Alcohol. 1998;33:606-8.
41. Yin M, Bradford BU, Wheeler MD, Uesugi T, Froh M, Goyert SM, et al. Reduced early alcohol-induced liver injury in CD14-deficient mice. J Immunol. 2001;166:4737-42.
42. Hill DB, D'Souza NB, Lee EY, Burikhanov R, Deaciuc IV, De Villiers JS. A role of interleukin-10 in alcohol-induced liver sensitization to bacterial lipopolysaccharide. Alcohol Clin Exp Res. 2002;26:74-82.
43. Lands WEM. Cellular signals in alcohol-induced liver injury: a review. Alcohol Clin Exp Res. 1995;19:928-38.
44. Chawla RK, Eastin CE, Watson WH, Lee EY, Bagby GJ, McClain CJ. S-adenosylmethionine deficiency and tumor necrosis factor alfa in endotoxin-induced hepatic injury. En: Mato JM, Caballero A, editors. Methionine metabolism: molecular mechanism and clinical implication. Madrid: CSIC; 1996. p. 263-70.
45. Roman J, Colell A, Blasco C, Caballería J, Parés A, Rodés J, et al. Differential role of etanol and acetaldehyde in the induction of oxidative stress in HEP G2 cells: effect on transcription factors AP-1 and NF-kappa B. Hepatology. 1999;30:1473-80.
46. García-Ruiz C, Morales A, Ballesta, Rodés J, Kaplowitz N, Fernández-Checa JC. Effect of chronic etanol feeding on glutathione and functional integrity of mitochondria in periportal perivenous rat hepatocytes. J Clin Invest. 1994;94:193-201.
47. Fernández-Checa JC, Kaplowitz N, García-Ruiz C, Colell A, Miranda M, Mari M, et al. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol. 1997;273:7G-17G.
48. Higuchi H, Adachi M, Miura S, Gores GJ, Ishii H. The mitochondrial permeability transition contributes to acute etanol-induced apoptosis in rat hepatocytes. Hepatology. 2001;34:320-8.
49. Zeldin G, Yang SQ, Yin M, Lin Hz, Rai R, Diehl AM. Alcohol and cytokine-inducible transcription factors. Alcohol Clin Exp Res. 1996;20:1639-45.
50. Vicente MM, Díez A, Gil B, Bermúdez JM, Gutiérrez F. Low serum levels of alpha-interferon, gamma-interferon, and interleukin 2 in alcoholic cirrhosis. Digest Dis Sci. 1991;36:1209-12.
51. Wang Y, Huang DS, Giger PT, Watson RR. Influence of chronic dietary ethanol on cytokine production by murine splenocytes and thymocytes. Alcohol Clin Exp Res. 1994;18:64-70.
52. Watzl B, López M, Shahbazian M, Chen G, Colombo LL, Huang D, et al. Diet and ethanol modulate immune responses in young C57BL/6 mice. Alcohol Clin Exp Res. 1993;17:623-30.
53. Daniluk J, Szuster-Ciesielska A, Drabko J, Kandefer-Szerszen M. Serum cytokine levels in alcohol-related liver cirrosis. Alcohol. 2001;23:29-34.
54. Nicolaou C, Chatzipanagiotou S, Tzivos D, Tzavellas EO, Boufidou F, Liappas IA. Serum cytokine concentrations in alcohol-dependent individuals without liver disease. Alcohol. 2004;32:243-7.
55. Laso FJ, Iglesias C, López A, Ciudad J, Pastor I, Orfao A. Chronic alcoholism is associated with an imbalanced production of Th1/Th2 cytokines by peripheral blood T cells. Alcohol Clin Exp Res. 1999;23:1306-11.
56. Laso FJ, Iglesias C, López A, Ciudad J, San Miguel JF, Orfao A. Increased interleukin-12 serum levels in chronic alcoholism. J Hepatol. 1998;28:771-7.
57. Heizel FP, Berko RM, Ling P, Hakimi J, Schoenhaut DS. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect Immun. 1994;62:4244-9.
58. Parent LJ, Ehrlich R, Matis L, Singer D. Ethanol: an enhancer of major histocompatibility complex antigen expression. FASEB J. 1987;1:469-73.
59. Singer DS, Parent LJ, Kolber MA. Ethanol: an enhancer of transplantation antigen expression. Alcohol Clin Exp Res. 1989;13:480-4.
60. Niemela O, Juvonen T, Parkkila S. Immunohistochemical demonstration of acethaldehyde-modified epitopes in human liver after alcohol consumption. J Clin Invest. 1991;87:1367-74.
61. Chedid A, Mendenhall CL, Mortiz T, and the Veterans Administration Cooperative Study n°. 275. Cell-mediated immune damage in alcoholic liver disease [abstract]. Hepatology. 1991;14:165A.
62. Chedid A, Mendenhall CL, and The Veterans Administration Cooperative Study n°. 275. Cell-mediated immunity in alcoholic liver disease. En: Seminara D, Watson RR, Pawlowski A, editors. Alcohol, imnunomodulation and AIDS. New York: Alan R Liss; 1990.p.321-32.
63. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology. 2003;38:1188-98.
64. Friedman S L. Stellate cell activation in alcoholic fibrosis: an overview. Alcohol Clin Exp Res. 1999;23:904-10.
65. Matsuoka M, Pham NT, Tsukamoto H. Differential effects of interleukin-1 alfa, tumor necrosis factor alpha and transforming growth factor beta-1 on cell proliferation and collagen formation by cultures fat-storin cells. Liver. 1989;9:71-8.
66. Matsuoka M, Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenic role in alcoholic liver fibrogenesis. Hepatology. 1990;11:599-605.
67. Kato J, Sato Y, Inui N, Nakano Y, Takimoto R, Takada K, et al. Ethanol induces transforming growth factor-α expression in hepatocytes, leading to estimulation of collagen sintesis by hepatic stellate cells. Alcohol Clin Exp Res. 2003;27:58S-63S.
68. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatoloy. 2003;37:1043-55.
69. Tsukamoto H. Cytokine regulation of hepatic stellate cells in liver fibrosis. Alcohol Clin Exp Res. 1999;23:911-6.
70. Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. Characterization of the activation of latent TGF beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: A self-regulation system. J Cell Biol. 1990;111:757-63.
71. Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores GJ. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003;83:655-63.
72. Friedman SL, Arthur MJP. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium: direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest 1989;84:1780-5.
73. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, et al. Hepatic expression of mature transforming growth factor B1 in transgenic mice results in multiple tissue lesion. Proc Natl Acad Sci USA. 1995;92:2572-6.
74. Bertolani C, Gelmini S, Petrai I, Orlando C, Marra F. Expression of adiponectin receptors by human hepatic stellate cells (HCS) modulates the profibrogenic actions of platelet-derived growth factor (PDGF). J Hepatol. 2004;40 Suppl 1:S7.
75. Xu A, Wang Y, Keshaw H, Xu LY, Lam KSL, Cooper GJS. The fat-derived adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91-100.
76. Milani S, Herbst H, Schuppan D, Grappone C, Pellegrini G, Pinzani M, et al. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol. 1994;144:528-37.
77. Arthur MJP, Friedman SL, Roll FJ, Bissell DM. Lipocytes from normal rat liver release a neutral metalloproteinase that degrades basement membrane (type IV) collagen. J Clin Invest. 1989;84:1076-85.
78. Tsukamoto H. Cytokine regulation of hepatic stellate cells in liver fibrosis. Alcohol Clin Exp Res 1999;23:911-6.
79. Thompson KC, Millward-Sadler GH, Gentry J, Sheron N. Transgenic IL-10 deleted mice develop increases fibrosis in a carbon tetrachloride-induced model of hepatic cirrhosis [abstract] Hepatology. 1997;26:335A.
80. Cabré E, Rodríguez - Iglesias P, Caballería J, Quer JC, Sánchez Lombraña JL, Parés A, et al. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology. 2000;32:36-42.
81. Lambert JC, Zhou Z, Wang L, Song Z, McClain CJ, Kang YJ. Prevention of alterations in intestinal permeability is involved in zinc inhibition of acute ethanol-induced liver damage in mice. J Pharmacol Exp Ther. 2003;305:880-6.
82. Peńa LR, Hill DB, McClain CJ. Treatment with glutathione precursor decreases cytokine activity. J Parenter Enteral Nutr. 1999;23:1-6.
83. Mato JM, Camara J, Fernández de Paz J, Caballería L, Coll S, Caballero A, et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomised, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol. 1999;30:1081-9.
84. Song Z, Barve S, Chen T, Nelson W, Uriarte S, Hill D, McClain C. S-adenosylmethionine (AdoMet) modulates endotoxin stimulated interleukin-10 production in monocytes. Am J Physiol Gastrointest Liver Physiol. 2003;284:G949-55.
85. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:1637-48.
86. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol. 2003;38:419-25.
87. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, et al. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology. 2004;39:1390-7.
88. Menon KV, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine CJ, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004;99:261-3.
89. Louis H, Van Laethem JL, Wu W, Quertinmont E, Degraef C, Van den Berg K, et al. Interleukin-10 controls neutrophilic infiltration, hepatocyte proliferation, and liver fibrosis in mice. Hepatology. 1998;28:1607-15.
90. Nakamura T, Sakata R, Ueno T, Sata M, Ueno H. Inhibition of transforming growth factor beta prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats. Hepatology. 2000;32:247-55.